Features

The education programs at DCAT Week 2025, held March 17–20, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the customer–supplier relationship. 

How is innovation inspiring and fueling the transformation of the bio/pharma industry? DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.

How did the bio/pharma industry perform in 2024, and what is the outlook for 2025 and near term?  What are the key growth areas and what headwinds and tailwinds does the industry face? How will new modalities factor into the growth prospects? Industry experts at DCAT Week 2025 provide the answers.

How are bio/pharma companies and their suppliers tackling difficult challenges in development, manufacturing, and the supply chain, including in risk management? How is supplier relationship management evolving? Senior executives at the education programs at DCAT Week will provide key insights.

What is the supply-demand outlook for fill–finish capacity in the CDMO/CMO sector? Is a capacity crunch or capacity easing in the making?

Evolving trade-related issues, such as tariffs, is one of many external variables that factor into the calculus in risk management. An executive panel at an upcoming DCAT Week program will provide perspectives on approaches to best identify, respond, and mitigate risk arising from geopolitical and other external events.

The pharma industry weighs in on the impact that US-imposed tariffs would have on products, manufacturing, and supply chains, particularly for generic drugs. With much uncertainty looming on how trade policy has and will evolve under a new US Administration, what is the latest?

While CEOs are optimistic about the global economy, macroeconomic volatility, inflation, and geopolitical uncertainty top the lists of risks of greatest concern, according to PwC’s 2025 Global CEO Survey, which fielded feedback from more than 4,700 CEOs globally across all industries.

Which new market entrants should be on the industry’s radar in 2025?  What new products, recently or expected to launch in 2025, show blockbuster potential? A look at the leading blockbuster contenders.    

Under a new US Administration, will drug-pricing reforms that call for the US government to negotiate prices for certain drugs continue? Will these reforms stay in play, and which products may be affected?